深话医改｜丙类目录即将落地，商保驶入快车道

Core Viewpoint - The introduction of the Category B directory is expected to enhance the development of commercial health insurance and basic medical insurance, supporting pharmaceutical innovation and meeting diverse public needs by 2025 [1][2]. Group 1: Impact on Healthcare and Insurance - The Category B directory is anticipated to create a positive cycle among "medical insurance - industry - livelihood," aligning with the goals of common prosperity and addressing the pressures on medical insurance funds due to an aging population [2]. - The directory will encourage commercial insurance companies to develop innovative insurance products, providing new growth opportunities [2]. - The directory will alleviate payment challenges for innovative drugs, helping pharmaceutical companies recover funds and promoting the healthy development of the pharmaceutical industry [2]. Group 2: International Experience and Management - International experiences show that directory management significantly improves the financial balance of medical and commercial insurance funds [3]. - Japan's National Health Insurance (NHI) system controls drug prices through a reimbursement directory, reducing the burden on medical insurance [3]. - Germany's dual-track system allows residents to choose between statutory health insurance and commercial health insurance, with a unified directory established through negotiations [5]. - The U.S. model, characterized by commercial health insurance dominance, has led to high drug prices but also significant bargaining power for insurance groups [5]. Group 3: Future Development of Health Insurance - The health insurance sector is expected to focus on two main lines: short-term scale expansion and long-term health management ecosystem development [6]. - By 2024, the health insurance market is projected to reach 977.3 billion yuan, with significant growth potential driven by policy support [6]. - The transition from critical illness insurance to health insurance requires a comprehensive restructuring of product forms, sales capabilities, and service systems [6]. Group 4: Investment Strategy - The healthcare industry is poised for a "Davis double hit," with a potential revaluation of the industry [8]. - Future medical expenses in China are estimated to grow at an annual rate of 5% to 10% over the next 5 to 10 years, with commercial health insurance expected to contribute significantly to payments for innovative drugs and services [8]. - Investment focus areas include innovative drugs, comprehensive service providers, and private medical terminals, which are expected to benefit from new payment sources and enhance growth potential [8].